Company Overview and News
International Business Machines Corp.'s IBM, -0.63% Watson Health head, Deborah DiSanzo, is leaving her role, Stat News reported on Friday. The high-profile departure, which a company spokesperson confirmed to Stat, comes as the famed computer system's usefulness in health care, including in treating cancer, has been criticized as overhyped, including in reports by Stat News and The Wall Street Journal.
October 18, 2018: Markets opened lower Thursday and if markets close at current levels, most of Tuesday’s 550-point gain will have been given back in two trading sessions. Chinese equity markets had rotten day Thursday as well and Wednesday’s FOMC minutes release indicated that rates are going to rise again in December. Every sector traded in the red with tech down the most followed by consumer discretionary stocks and industrials.
IBM HD CATR CAT AAPL
The following slide deck was published by International Business Machines Corporation in conjunction with their 2018 Q3 earnings call.
2018-10-17 sec.gov - 1
International Business Machines Corp. shares were on track for their worst day in six months Wednesday, as investors appeared to grow impatient with the pace of the tech giant’s growth in new businesses after it snapped a short-lived revenue growth streak.
After International Business Machines Corp. (NYSE: IBM) reported its third-quarter financial results after the markets closed on Tuesday, investors ultimately were hugely disappointed and sent shares lower, making it the worst performing Dow Jones industrials stock on Wednesday. However, analysts maintained optimism for the tech giant, looking past this hiccup.
The stock market has challenged investors for all of 2018. In addition to the effects of global saber rattling amid the U.S.-China trade war, Wall Street has seen volatility come back in force. As a result, we had sharp corrections in stocks, especially in the Nasdaq Composite. Microsoft (NASDAQ:MSFT) is one of the lucky stocks that is still up 25% year-to-date while others like Alphabet (NASDAQ:GOOGL) are back to flat or worse.
IBM AMZN GOOGL MSFT NFLX
A seemingly perennial Dow Jones laggard, International Business Machines (NYSE:IBM) had just started to gain its mojo in the second half of this year. Many investors were willing to give IBM stock another look as evidence indicated momentum towards relevant, lucrative businesses.
IBM AMZN MSFT
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to IBM / International Business Machines Corp. on message board site Silicon Investor.
as of ET